Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649656 | 1.00 | CA2 (0.44) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL418942 | 1.00 | CA2 (0.44) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL4929770 | 0.88 | CA2 (0.42) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL929572 | 0.88 | CA2 (0.42) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL1243925 | 0.88 | CA2 (0.42) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL7154999 | 0.86 | CA2 (0.50) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL18817541 | 0.86 | CA2 (0.50) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL714194 | 0.86 | CA2 (0.41) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL20707235 | 0.86 | CA2 (0.41) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL21409717 | 0.84 | CA2 (0.40) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125614-A1 | IONIZABLE CATIONIC LIPIDS | AKAGERA MEDICINES, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12606773-B2 | Ionizable cationic lipids | AKAGERA MEDICINES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260077038-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069684-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20260055335-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS | AKAGERA MEDICINES, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20260007741-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES | AKAGERA MEDICINES, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20250387462-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | AKAGERA MEDICINES, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-1061062-A1 | PROCESS FOR PRODUCING BUTANETRIOL DERIVATIVE | DAISO CO., LTD. (JP) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000055155-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-09-21 | — | — | WO | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| US-5688826-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0774461-A1 | Excitatory amino acid derivatives | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| US-4855481-A | Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein | MERCK FROSST CANADA, INC. (CA) | 1989-08-08 | — | — | US | disclosed |
| US-4611068-A | Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein | MERCK FROSST CANADA, INC. (CA) | 1986-09-09 | — | — | US | disclosed |
| EP-0055239-B1 | NOVEL DERIVATIVES OF GUANINE | Astra Läkemedel Aktiebolag (SE) | 1986-07-16 | — | — | EP | disclosed |
| EP-0183132-A2 | A process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein | MERCK FROSST CANADA INC. (CA) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069684-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | PHOSPHO1, PLTP, SGMS1 | CA2 4138/4885ALDH1A1 4716/4885NPSR1 2677/4885 |
| US-20250387462-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | CD4, MICA, LNPK | CA2 4567/4885ALDH1A1 4826/4885NPSR1 3963/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | CA2 1668/4885ALDH1A1 951/4885NPSR1 1392/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | CA2 1189/4885ALDH1A1 1848/4885NPSR1 4103/4885 |
| US-20260007741-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES | TLR9, TLR3, TLR8 | CA2 4781/4885ALDH1A1 4581/4885NPSR1 3131/4885 |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | CA2 2981/4885ALDH1A1 2522/4885NPSR1 3105/4885 |
| US-20260077038-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | PHOSPHO1, LNPK, SGMS2 | CA2 3487/4885ALDH1A1 4782/4885NPSR1 3124/4885 |
| US-20260125614-A1 | IONIZABLE CATIONIC LIPIDS | CPT2, NPC1L1, PNPLA2 | CA2 1967/4885ALDH1A1 3307/4885NPSR1 3930/4885 |
| US-12606773-B2 | Ionizable cationic lipids | NPC1L1, MCOLN1, SLC22A4 | CA2 1001/4885ALDH1A1 2574/4885NPSR1 3915/4885 |
| US-20260055335-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS | CD4, LDLR, CD2BP2 | CA2 4227/4885ALDH1A1 2719/4885NPSR1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.